Skip to main content
Signal8

Incannex Healthcare Inc. (IXHL)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Incannex Healthcare Limited logo

Incannex Healthcare Limited

NASDAQ:IXHLHealthcare
AH+0.00%$2.19
Close$2.19-2.23%
Mkt Cap$27.47M
Float11.07M
O/S12.54M
VOL91K sh
$ Vol$202K
RVOL1.16×
Inst Own4.5%
EarningsNov 13 · in 3d
Dilution
Incannex Healthcare Limited logoNASDAQ:IXHLAH$2.19+0.00%
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 20262.282.282.162.1991,030
Nov 6, 20262.322.332.162.24107,794
Nov 5, 20262.482.642.242.27123,330
Nov 4, 20262.552.662.492.4936,958
Nov 3, 20262.402.552.402.5066,505
Nov 2, 20262.562.632.172.38148,878
Oct 30, 20262.582.622.502.52102,877
Oct 29, 20262.672.752.582.5856,896
Oct 28, 20262.652.792.622.7148,135
Oct 27, 20262.612.692.562.6264,699
Oct 26, 20262.642.672.582.6159,567
Oct 23, 20262.592.692.572.6440,250
Oct 22, 20262.732.752.552.60138,401
Oct 21, 20262.782.812.752.7630,837
Oct 20, 20262.742.862.742.7552,613
Oct 19, 20262.802.852.752.7668,748
Oct 16, 20262.882.942.812.8229,161
Oct 15, 20262.842.902.752.8886,728
Oct 14, 20262.912.932.842.8680,040
Oct 13, 20262.952.992.882.9157,941
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
InsiderTypeShares
Widdows Peter profile photoWiddows PeterGrant/Award1.69M
Clark Robert profile photoClark RobertGrant/Award1.69M
Anastassov George profile photoAnastassov GeorgeGrant/Award1.69M
Valentine Troy profile photoValentine TroyGrant/Award11.30M
Swan Joseph profile photoSwan JosephGrant/Award869.6K
Latham Joel profile photoLatham JoelGrant/Award22.61M
Shareholders
4.5%
Institutional
(14)
11.5%
Insiderⓘ
(7)
0.4%
5%+ Owners
(1)
83.6%
Unattributed (incl. retail)ⓘ
Institutional4.5%
Insider11.5%
5%+ Beneficial0.4%
Unattributed (incl. retail)83.6%
Top Shareholders
NameShares%
Latham Joel profile photo
Latham Joel
CEO and President, Director
806.2K6.4%
Valentine Troy profile photo
Valentine Troy
Director
400.1K3.2%
AdvisorShares Investments LLC logo
AdvisorShares Investments LLC
168.3K1.3%
LPL Financial LLC logo
LPL Financial LLC
153.1K1.2%
MILLENNIUM MANAGEMENT LLC logo
MILLENNIUM MANAGEMENT LLC
95.3K0.8%
Anastassov George profile photo
Anastassov George
Director
81.9K0.7%
JANE STREET GROUP, LLC logo
JANE STREET GROUP, LLC
78.2K0.6%
Widdows Peter profile photo
Widdows Peter
Director
65.3K0.5%
Clark Robert profile photo
Clark Robert
Director
59.6K0.5%
L1 Capital Global Opportunities Master Fund, Ltd. logo
L1 Capital Global Opportunities Master Fund, Ltd.
· may incl. warrants· filed May 2025
49.0K0.4%
Sources: 13F, Form 4, 13D/13GO/S: 12.5M · as of 24 Sep 2026 · SEC filings
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products.

The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand.

Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.

Key Metrics
Market Cap$27.47M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership4.50%

based on 12.54M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryAUAU
IPO DateMar 2, 2022
Shares Outstanding12.54M
Authorized Shares
Float11.07M
52-Week Range
$2.16$14.91
$2.19(0th percentile)
Volume
Average Daily Volume78.20K
91.03K today vs 78.20K avg(+16%)

30d Avg

78.20K

60d Avg

84.12K

90d Avg

82.56K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...